IL314717A - Crystalline prostacyclin (IP) receptor agonist and uses thereof - Google Patents
Crystalline prostacyclin (IP) receptor agonist and uses thereofInfo
- Publication number
- IL314717A IL314717A IL314717A IL31471724A IL314717A IL 314717 A IL314717 A IL 314717A IL 314717 A IL314717 A IL 314717A IL 31471724 A IL31471724 A IL 31471724A IL 314717 A IL314717 A IL 314717A
- Authority
- IL
- Israel
- Prior art keywords
- prostacyclin
- crystalline
- receptor agonist
- agonist
- receptor
- Prior art date
Links
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title 2
- 229960001123 epoprostenol Drugs 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310469P | 2022-02-15 | 2022-02-15 | |
| PCT/US2023/013032 WO2023158634A1 (en) | 2022-02-15 | 2023-02-14 | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314717A true IL314717A (en) | 2024-10-01 |
Family
ID=87578956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314717A IL314717A (en) | 2022-02-15 | 2023-02-14 | Crystalline prostacyclin (IP) receptor agonist and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12098116B2 (https=) |
| EP (1) | EP4479374A1 (https=) |
| JP (1) | JP2025506098A (https=) |
| KR (1) | KR20240149924A (https=) |
| CN (1) | CN118922402A (https=) |
| AU (1) | AU2023222747A1 (https=) |
| CA (1) | CA3248736A1 (https=) |
| IL (1) | IL314717A (https=) |
| WO (1) | WO2023158634A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023158634A1 (en) | 2022-02-15 | 2023-08-24 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
| US20240139207A1 (en) | 2022-10-31 | 2024-05-02 | United Therapeutics Corporation | Methods for treating pulmonary hypertension |
| US20250282716A1 (en) | 2024-03-11 | 2025-09-11 | United Therapeutics Corporation | Methods of making ip-receptor agonists |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2945530A1 (de) | 1979-11-10 | 1981-06-04 | Chemische Werke Hüls AG, 4370 Marl | Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide |
| JPH03160438A (ja) | 1989-11-20 | 1991-07-10 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| EP0442448A3 (en) | 1990-02-13 | 1992-08-12 | Bristol-Myers Squibb Company | Heterocyclic carboxylic acids and esters |
| CA2085844A1 (en) | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
| JPH06329598A (ja) | 1993-05-19 | 1994-11-29 | Daicel Chem Ind Ltd | エステルの製造方法 |
| DE4318889A1 (de) | 1993-06-07 | 1994-12-08 | Bayer Ag | Verfahren zur Herstellung von organischen Carbamaten |
| TW282456B (https=) | 1994-03-10 | 1996-08-01 | Fujisawa Yakusin Kogyo Kk | |
| JPH11269138A (ja) | 1998-03-20 | 1999-10-05 | Mitsubishi Paper Mills Ltd | 有機塩基発生剤 |
| US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| KR100523119B1 (ko) | 2000-03-16 | 2005-10-20 | 에프. 호프만-라 로슈 아게 | Ｉｐ 길항제로서의 카복실산 유도체 |
| WO2002055484A1 (en) | 2001-01-12 | 2002-07-18 | Takeda Chemical Industries, Ltd. | Biaryl compound, process for producing the same, and agent |
| TWI316055B (https=) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| CN101284773A (zh) | 2001-08-09 | 2008-10-15 | 小野药品工业株式会社 | 羧酸衍生物及以它为活性成分的药剂 |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TWI293715B (en) | 2002-10-10 | 2008-02-21 | Sipix Imaging Inc | A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display |
| CN1735598A (zh) | 2002-11-11 | 2006-02-15 | 拜耳医药保健股份公司 | 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物 |
| RU2351590C2 (ru) | 2003-02-10 | 2009-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения диариламина |
| GB0317498D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| JP4339890B2 (ja) | 2003-09-22 | 2009-10-07 | エフ．ホフマン−ラ ロシュ アーゲー | アミノアルキルアミド置換シクロヘキシル誘導体 |
| JP4402413B2 (ja) | 2003-09-29 | 2010-01-20 | 財団法人２１あおもり産業総合支援センター | Ｕ字型化合物およびこれを含む液晶組成物 |
| DE102004006785A1 (de) | 2004-02-11 | 2005-09-08 | Mayr, Herbert, Prof. Dr. | Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure |
| JP2008510726A (ja) | 2004-08-20 | 2008-04-10 | エントレメッド インコーポレイテッド | プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法 |
| JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
| JP4792731B2 (ja) | 2004-11-12 | 2011-10-12 | Ｄｉｃ株式会社 | 重合性液晶組成物及び当該組成物の硬化物 |
| WO2007051255A1 (en) | 2005-11-04 | 2007-05-10 | The University Of Sydney | Process for the preparation of compounds containing an azacyclic ring system |
| JP2007161867A (ja) | 2005-12-14 | 2007-06-28 | Toyo Ink Mfg Co Ltd | インキ組成物 |
| US20080075692A1 (en) | 2006-05-09 | 2008-03-27 | Perrine Susan P | Methods for treating blood disorders |
| WO2009117095A1 (en) | 2008-03-18 | 2009-09-24 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| US20110224262A1 (en) | 2008-11-26 | 2011-09-15 | Arena Pharmaceuticals, Inc. | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| ES2548882T3 (es) | 2008-12-08 | 2015-10-21 | Arena Pharmaceuticals, Inc. | Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos |
| WO2011037613A1 (en) | 2009-09-23 | 2011-03-31 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| US10537546B2 (en) | 2014-10-23 | 2020-01-21 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the PGI2 receptor |
| US12377067B2 (en) | 2016-11-10 | 2025-08-05 | Arena Pharmaceuticals, Inc. | Methods of treating PAH with combinations of ralinepag and other agents |
| IL268997B2 (en) | 2017-03-01 | 2023-09-01 | Arena Pharm Inc | Preparations containing pgi2 receptor agonists and processes for their preparation |
| CA3072079A1 (en) | 2017-08-07 | 2019-02-14 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| EP3796902A1 (en) | 2018-05-16 | 2021-03-31 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| WO2020048299A1 (zh) | 2018-09-06 | 2020-03-12 | 广东东阳光药业有限公司 | 药物共晶体及其制备方法 |
| WO2023158634A1 (en) | 2022-02-15 | 2023-08-24 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
| AU2023236147A1 (en) | 2022-03-17 | 2024-09-19 | United Therapeutics Corporation | Ralinepag prodrugs and uses thereof |
-
2023
- 2023-02-14 WO PCT/US2023/013032 patent/WO2023158634A1/en not_active Ceased
- 2023-02-14 EP EP23756804.3A patent/EP4479374A1/en active Pending
- 2023-02-14 CA CA3248736A patent/CA3248736A1/en active Pending
- 2023-02-14 IL IL314717A patent/IL314717A/en unknown
- 2023-02-14 AU AU2023222747A patent/AU2023222747A1/en active Pending
- 2023-02-14 JP JP2024543285A patent/JP2025506098A/ja active Pending
- 2023-02-14 US US18/169,016 patent/US12098116B2/en active Active
- 2023-02-14 CN CN202380024450.1A patent/CN118922402A/zh active Pending
- 2023-02-14 KR KR1020247029983A patent/KR20240149924A/ko active Pending
-
2024
- 2024-08-19 US US18/808,809 patent/US20240409503A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240409503A1 (en) | 2024-12-12 |
| AU2023222747A1 (en) | 2024-08-22 |
| KR20240149924A (ko) | 2024-10-15 |
| CN118922402A (zh) | 2024-11-08 |
| JP2025506098A (ja) | 2025-03-07 |
| CA3248736A1 (en) | 2023-08-24 |
| US12098116B2 (en) | 2024-09-24 |
| WO2023158634A1 (en) | 2023-08-24 |
| US20230406815A1 (en) | 2023-12-21 |
| EP4479374A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314717A (en) | Crystalline prostacyclin (IP) receptor agonist and uses thereof | |
| EP4212527A4 (en) | GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF | |
| EP4574821B8 (en) | Thrb receptor agonist compound and preparation method and use thereof | |
| EP4130005A4 (en) | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF | |
| SMT202400427T1 (it) | Nuovo uso dell'agonista del recettore dell'angiotensina ii di tipo 2 | |
| EP4019524A4 (en) | HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF | |
| EP3852749A4 (en) | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | |
| CA3263797A1 (en) | Muscarinic receptor agonists | |
| IL300000A (en) | PPAR agonist - crystalline delta | |
| EP4091623A4 (en) | CALCIUM SENSING RECEPTOR AGONIST COMPOUND AND ITS APPLICATION | |
| ZA202307999B (en) | Carboxy substituted glucocorticoid receptor agonists | |
| EP4348428A4 (en) | MICROELECTRONIC CIRCUIT WITH DYNAMICALLY ADJUSTABLE COVERAGE FOR IN-SITU TIMING EVENT MONITORS | |
| CA3306882A1 (en) | Composition comprising beta-2-adrenergic receptor agonist for transdermal administration | |
| HK40084786A (en) | Gip receptor agonist peptide compounds and uses thereof | |
| HK40108564A (en) | Combination of bitter receptor agonist and gut-signaling compound | |
| CA3272753A1 (en) | Composition comprising glp-1 receptor agonist and acat inhibitor | |
| HK40116229A (en) | Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor | |
| CA3276371A1 (en) | Galanin-2 receptor agonists | |
| GB202408483D0 (en) | Receptor agonists | |
| CA3276544A1 (en) | Glucocorticoid receptor agonist and conjugate thereof | |
| AU2021903786A0 (en) | Novel P2X7 receptor antagonists | |
| HK40122612A (en) | Glucocorticoid receptor agonists | |
| CA3291371A1 (en) | G-protein coupled receptor antagonist | |
| CA3275190A1 (en) | Inhalable hormone receptor agonist formulations | |
| EP4353248A4 (en) | CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF |